NASDAQ:MRTX - Mirati Therapeutics Stock Price, Forecast & News

Mirati Therapeutics trades on the NASDAQ under the ticker symbol "MRTX."

Mirati Therapeutics Inc (NASDAQ:MRTX) posted its quarterly earnings data on Monday, November, 4th. The biotechnology company reported ($1.38) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.25) by $0.13. The biotechnology company had revenue of $0.99 million for the quarter, compared to analysts' expectations of $0.50 million. Mirati Therapeutics had a negative return on equity of 48.60% and a negative net margin of 2,698.66%. View Mirati Therapeutics' Earnings History.

Mirati Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for Mirati Therapeutics.

17 brokers have issued 1-year price targets for Mirati Therapeutics' shares. Their forecasts range from $81.00 to $134.00. On average, they anticipate Mirati Therapeutics' share price to reach $107.93 in the next twelve months. This suggests a possible upside of 19.5% from the stock's current price. View Analyst Price Targets for Mirati Therapeutics.

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mirati Therapeutics in the last year. There are currently 1 sell rating, 4 hold ratings and 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Mirati Therapeutics.

Press coverage about MRTX stock has been trending somewhat positive this week, according to InfoTrie. The research firm scores the sentiment of press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Mirati Therapeutics earned a news sentiment score of 0.8 on InfoTrie's scale. They also gave headlines about the biotechnology company a news buzz of 3.0 out of 10, indicating that recent press coverage is unlikely to have an effect on the company's share price in the near future. View News Stories for Mirati Therapeutics.

Some companies that are related to Mirati Therapeutics include Genmab A/S (GNMSF), Alnylam Pharmaceuticals (ALNY), GALAPAGOS NV/S (GLPG), Elanco Animal Health (ELAN), Mylan (MYL), Teva Pharmaceutical Industries (TEVA), Bausch Health Companies (BHC), Beigene (BGNE), Ono Pharmaceutical (OPHLF), Catalent (CTLT), Sarepta Therapeutics (SRPT), Ionis Pharmaceuticals (IONS), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO) and Dr.Reddy's Laboratories (RDY).

Based on aggregate information from My MarketBeat watchlists, some companies that other Mirati Therapeutics investors own include AbbVie (ABBV), Arrowhead Pharmaceuticals (ARWR), Micron Technology (MU), Netflix (NFLX), NVIDIA (NVDA), Viking Therapeutics (VKTX), Bausch Health Companies (BHC), Advanced Micro Devices (AMD), Amarin (AMRN) and Exelixis (EXEL).

Mirati Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional investors include Rhenman & Partners Asset Management AB (0.32%), California Public Employees Retirement System (0.16%), Columbus Circle Investors (0.14%), Strs Ohio (0.01%), JGP Global Gestao de Recursos Ltda. (0.01%) and Tocqueville Asset Management L.P. (0.01%). Company insiders that own Mirati Therapeutics stock include Aaron I Davis, Avoro Capital Advisors Llc, Boxer Capital, Llc, Bruce L A Carter, Charles M Baum, Christopher C Lemasters, Craig A Johnson, Jamie A Donadio, Jamie Christensen, Michael G Grey and Venbio Select Advisor Llc. View Institutional Ownership Trends for Mirati Therapeutics.

MRTX stock was sold by a variety of institutional investors in the last quarter, including California Public Employees Retirement System and Columbus Circle Investors. Company insiders that have sold Mirati Therapeutics company stock in the last year include Avoro Capital Advisors Llc, Boxer Capital, Llc, Bruce L A Carter, Charles M Baum, Christopher C Lemasters, Craig A Johnson, Jamie A Donadio, Michael G Grey and Venbio Select Advisor Llc. View Insider Buying and Selling for Mirati Therapeutics.

MRTX stock was acquired by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB, JGP Global Gestao de Recursos Ltda., Tocqueville Asset Management L.P., Strs Ohio, Zurcher Kantonalbank Zurich Cantonalbank and Nisa Investment Advisors LLC. Company insiders that have bought Mirati Therapeutics stock in the last two years include Boxer Capital, Llc and Venbio Select Advisor Llc. View Insider Buying and Selling for Mirati Therapeutics.

Shares of MRTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of MRTX stock can currently be purchased for approximately $90.35.

Mirati Therapeutics has a market capitalization of $3.56 billion and generates $12.93 million in revenue each year. The biotechnology company earns $-98,420,000.00 in net income (profit) each year or ($3.19) on an earnings per share basis. Mirati Therapeutics employs 63 workers across the globe.View Additional Information About Mirati Therapeutics.

The official website for Mirati Therapeutics is http://www.mirati.com/.

Mirati Therapeutics' mailing address is 9393 TOWNE CENTRE DRIVE SUITE 200, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-332-3410 or via email at [email protected]